Luz Hammershaimb

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr et al. · Journal of Clinical Oncology · 2000 · 1.4K citations

Medicine, Oncology, Pharmacology +10

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α_vβ₃, ± dacarbazine in patients with stage IV metastatic melanoma

Peter Hersey, Jeffrey A. Sosman, Steven O’Day et al. · Cancer · 2010 · 186 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Douglas G. McNeel, Jens C. Eickhoff, Fred T. Lee et al. · Clinical Cancer Research · 2005 · 158 citations

Medicine, Oncology, Pharmacology +17

Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group.

F. Moffat, Carl Pinsky, Luz Hammershaimb et al. · Journal of Clinical Oncology · 1996 · 126 citations

Medicine, Nuclear Medicine, Surgery +17

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Catherine Delbaldo, Éric Raymond, Karina Vera et al. · Investigational New Drugs · 2007 · 101 citations

Pharmacy, Oncology, Pharmacokinetics +17